UBS Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-171
| Closed | -$23K | – | 8617 |
|
|
2020
Q4 | $23K | Buy |
171
+155
| +969% | +$20.8K | ﹤0.01% | 5848 |
|
|
2020
Q3 | $1K | Sell |
16
-316
| -95% | -$19.8K | ﹤0.01% | 7020 |
|
|
2020
Q2 | $16K | Sell |
332
-2,929
| -90% | -$141K | ﹤0.01% | 5867 |
|
|
2020
Q1 | $160K | Sell |
3,261
-8,381
| -72% | -$411K | ﹤0.01% | 4057 |
|
|
2019
Q4 | $668K | Buy |
11,642
+10,781
| +1,252% | +$619K | ﹤0.01% | 3660 |
|
|
2019
Q3 | $31K | Sell |
861
-475
| -36% | -$17.1K | ﹤0.01% | 5521 |
|
|
2019
Q2 | $41K | Buy |
1,336
+1,174
| +725% | +$36K | ﹤0.01% | 5231 |
|
|
2019
Q1 | $4K | Sell |
162
-573
| -78% | -$14.1K | ﹤0.01% | 6457 |
|
|
2018
Q4 | $10K | Sell |
735
-972
| -57% | -$13.2K | ﹤0.01% | 6330 |
|
|
2018
Q3 | $17K | Buy |
1,707
+121
| +8% | +$1.21K | ﹤0.01% | 5984 |
|
|
2018
Q2 | $32K | Buy |
+1,586
| New | +$32K | ﹤0.01% | 5434 |
|